Akebia Therapeutics, Inc. 8-K

What Happened

• Akebia Therapeutics, Inc. (AKBA) filed a Form 8-K dated April 1, 2026 under Item 9.01 to furnish exhibits, including a press release issued that same day. The filing was signed by President and CEO John P. Butler.

Key Details

• Filing date: April 1, 2026.
• Exhibits included: 99.1 (Press Release dated April 1, 2026) and 104 (Inline XBRL cover page).
• Reported item: 9.01 (Financial Statements and Exhibits) — the filing furnishes exhibits only; no earnings (Item 2.02), executive changes (Item 5.02), mergers (Item 1.01), or bankruptcies (Item 1.03) were reported in this 8-K.
• Signed by: John P. Butler, President and Chief Executive Officer.

Why It Matters

• This 8-K primarily notifies investors that Akebia has released a press statement; the filing itself does not disclose new financial results, leadership changes, or transactions. Investors should open Exhibit 99.1 (the April 1 press release) to determine if it contains material information (e.g., earnings, corporate developments, product or regulatory news) that could affect the stock.